Beta

Scisparc ltd.SPRC.US Overview

US StockHealthcare
(No presentation for SPRC)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

SPRC AI Insights

SPRC Overall Performance

SPRC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SPRC Recent Performance

-4.47%

Scisparc ltd.

-1.10%

Avg of Sector

-0.49%

S&P500

SPRC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check SPRC's Trend

SPRC Key Information

SPRC Valuation Metrics

SPRC Profile

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Price of SPRC

SPRC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SPRC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-210.41
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
2.90
PB Ratio
0.49
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
21.90%
Net Margin
-1312.84%
Revenue Growth (YoY)
-46.94%
Profit Growth (YoY)
-74.53%
3-Year Revenue Growth
-24.45%
3-Year Profit Growth
105.10%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-210.41
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
2.90
PB Ratio
0.49
Price-to-FCF
-
Gross Margin
21.90%
Net Margin
-1312.84%
Revenue Growth (YoY)
-46.94%
Profit Growth (YoY)
-74.53%
3-Year Revenue Growth
-24.45%
3-Year Profit Growth
105.10%

  • When is SPRC's latest earnings report released?

    The most recent financial report for Scisparc ltd. (SPRC) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SPRC's short-term business performance and financial health. For the latest updates on SPRC's earnings releases, visit this page regularly.

  • What is the operating profit of SPRC?

    According to the latest financial report, Scisparc ltd. (SPRC) reported an Operating Profit of -9.15M with an Operating Margin of -1,985.03% this period, representing a decline of 359.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SPRC's revenue growth?

    In the latest financial report, Scisparc ltd. (SPRC) announced revenue of 461K, with a Year-Over-Year growth rate of -45.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does SPRC have?

    At the end of the period, Scisparc ltd. (SPRC) held Total Cash and Cash Equivalents of 1.55M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SPRC's EPS continuing to grow?

    According to the past four quarterly reports, Scisparc ltd. (SPRC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -161.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SPRC?

    Scisparc ltd. (SPRC)'s Free Cash Flow (FCF) for the period is -1.86M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 15.33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.